The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
Tóm tắt
Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excretion. The subjects were 102 UC patients who were newly prescribed MMX alone to induce remission. Their stools were evaluated on the Bristol Stool Form Scale (BSFS), the presence/absence of insoluble MMX excretion was investigated in interviews, and defecation frequency at the start of treatment and disease type were retrospectively investigated by examining their medical records. The insoluble excretion rate (IER) was 14.7%. It tended to be higher in the patients with left-sided colitis or extensive colitis, although the differences among the disease types were not significant (p = 0.053). The mean defecation frequency of the patients that reported insoluble MMX excretion was significantly higher than that of the patients that did not report it (6.27 ± 5.28 vs. 3.69 ± 3.17, p < 0.05). The IER tended to be higher among the patients with soft stools (4.5%, 21.9%, and 23.1% in those with BSFS scores of ≤ 4, 5, and ≥ 6, respectively). In ROC analysis of defecation frequency, ≥ 3.5 defecations was found to exhibit sensitivity and specificity of 66.7% and 65.5%, respectively, for predicting insoluble MMX excretion. The likelihood of insoluble MMX excretion is influenced by defecation frequency and the extent of inflammation. It is important to keep the possibility of insoluble excretion in mind when prescribing MMX.
Tài liệu tham khảo
Oh-oka K, Kojima Y, Uchida K, Yoda K, Ishimaru K, Nakajima S, Hemmi J, Kano H, Fujii-Kuriyama Y, Katoh R, Ito H, Nakao A. Induction of colonic regulatory T cells by mesalamine by activating the aryl hydrocarbon receptor. Cell Mol Gastroenterol Hepatol. 2017;1:135–51.
Alistair Murray, Tran M Nguyen, Claire E Parker, Brian G Feagan, John K MacDonald. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020; 8.
William Jeffery Sandborn MA, Kamm GR, Lichtenstein A, Lyne T, Butler RE, Joseph MMX. Multi matrix system mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials®. Alimentary Pharmacol Therapeuics. 2007;26:205–15.
Koh H, Lee MJ, Kim MJ, Shin JI, Chung KS. Simple diagnostic approach to childhood fecal retention using the Leech score and Bristol stool form scale in medical practice. J Gastroenterol Hepatol. 2010;2:334–8.
Corsetti M, De Nardi P, Di Pietro S, et al. Rectal distensibility and symptoms after stapled and Milligan-Morgan operation for hemorrhoids. J Gastrointest Surg. 2009;12:2245–51.
Hussain FN, Ajjan RA, Moustafa M, Weir NW, Riley SA. Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration. Br J Clin Pharmacol. 1998;2:173–5.
Van Camp A, Vanuytsel T, Brouwers J, Augustijns P. The effect of esomeprazole on the upper GI tract release and systemic absorption of mesalazine from colon targeted formulations. Int J Pharmaceut. 2022;619:121701.
Shimodaira Y, Onochi K, Watanabe K, Takahashi So, Fukuda S, Watanabe N, Koizumi S, Matsuhashi T, Iijima K. Effect of acid-reducing agents on clinical relapse in ulcerative colitis with pH-dependent-released 5-aminosalicylic acid: a multicenter retrospective study in Japan. Intestinal Res. 2021;2:225–31.
Kao J, Kwok K. Kiron M Das: Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine. J Clin Gastroenterol. 2010;8:531–5.
Cohen RD. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Therapeuics. 2006;3:465–74.
Qureshi AI, Cohen RD. Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev. 2005;2:281–302.
Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Exp Rev Clin Pharmacol. 2012;2:113–23.
D’Incà R, Paccagnella M, Cardin R, Pathak S, Baldo V, Giron MC, Sturniolo GC. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. World J Gastroenterol. 2013;34:5565–70.
Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F, Savarino V, Sturniolo GC, Vecchi M, Ardia A, Bellinvia S. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Therapeuics. 2009;9:908–18.
Fukuda T, Naganuma M, Takabayashi K, Hagihara Y, Tanemoto S, Nomura E, Yoshimatsu Y, Sugimoto S, Nanki K, Mizuno S, Mikami Y, Fukuhara K, Sujino T, Mutaguchi M, Inoue N, Ogata H, Iwao Y, Abe T, Kanai T. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine. J Gastroenterol Hepatol. 2020;11:1878–85.
Tong JL, Huang ML, Xu XT, Qiao YQ, Ran ZH. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis. J Digest Dis. 2012;4:200–7.
Abinusawa A, Tenjarla S. Release of 5-aminosalicylic acid (5-ASA) from mesalamine formulations at various pH levels. Adv Ther. 2015;5:477–84.
Yasutomi E, Hiraoka S, Yamamoto S, Oka S, Hirai M, Yamasaki Y, Inokuchi T, Kinugasa H, Takahara M, Harada K, Kato J, Okada H. Switching between three types of mesalazine formulation and sulfasalazine in patients with active ulcerative colitis who have already received high-dose treatment with these agents. J Clin Med. 2019;12:2109.
Gifford AE, Berg AH, Lahiff C, Cheifetz AS, Horowitz G, Moss AC. A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. Am J Gastroenterol. 2013;2:249–55.
Cuffari C, Pierce D, Korczowski B, Fyderek K, Van Heusen H, Hossack S, Martin P. Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis. Drug Des Dev Therapy. 2016;10:593–607.